Funded by the Ministry of Health and Long Term Care and managed by Cancer Care Ontario, the Ontario Breast Screening Program (OBSP) provides province wide, high-quality, OHIP-covered breast screening mammography services. The OBSP offers important advantages including scheduling of all screening appointments, sending recall and result letters to participants, and arranging follow-up services when results require further testing.
Screening Mammography plays an important part in early detection of breast cancer. Regular screening mammograms can detect cancer in its early stages which means there may be more treatment options, is less likely to spread and a better chance of treating the cancer successfully.
Persons 50 to 74 who are eligible are encouraged to have a mammogram at least every two years to detect changes in breast tissue that are too small to feel or see.
People ages 40 to 49 should make an informed decision about whether breast cancer screening is right for them. Generally, people ages 40 to 49 have a lower chance of getting breast cancer than people ages 50 to 74, so the balance of potential benefits to potential harms of breast cancer screening may be different for people ages 40 to 49 than for people ages 50 to 74.
The Ontario Breast Screening Program is encouraging people ages 40 to 49 to have a conversation with their primary care provider or a Health811 navigator to discuss their personal risk for breast cancer, the potential benefits and potential harms of breast cancer screening and what matters most to them in taking care of their health.
The OBSP Program does not require a requisition from your doctor however, the following requirements must be met to be a part of the program:
The Ontario Breast Screening Program offers breast cancer screening to women, Two-Spirit people, trans people and nonbinary people ages 40 to 74 if they:
Persons over the age of 74 who meet the above requirements can still take part in the program with a physician requisition.
Studies have shown that ultrasound and magnetic resonance imaging (MRI) combined with mammography can aid in diagnosis of breast concerns. However, both MRI and ultrasound show more findings that are not cancer, which can result in added testing, stress and unnecessary biopsies. Mammography remains to be the gold standard for breast cancer screening for most people.
Breasts contain glandular, connective and fat tissue. Breast density is a term that describes the relative amount of these different types of breast tissue as seen on a mammogram. Dense breasts have relatively high amounts of glandular tissue and fibrous connective tissue and relatively low amounts of fatty breast tissue.
A mammogram is a low dose x-ray of the breasts. The x-ray dose from a mammogram is very low and the exposure to the thyroid is negligible. Thyroid exposure has been carefully studied and is so small that it is equivalent to 30 minutes of background radiation (the naturally occurring radiation we all get every day from the environment). There is no risk to the thyroid during a mammogram and a thyroid shield is not necessary to wear during the exam.
Today, modern mammography equipment produces high quality breast images with low doses of radiation. The total dose for a mammogram with two views of each breast (four pictures) is about 0.4mSv. The average annual effective dose from natural background radiation is about 1.8mSv in Canada and 2.4mSv worldwide.
Whenever having a medical procedure that involves radiation, an individual must always measure the risk vs the benefit. The benefit of an accurate diagnosis far out weights the risk.
Where possible and when it does not unduly delay care, screening appointments for participants should be scheduled before they receive any COVID-19 vaccine dose (or any other vaccine) or 6 weeks after vaccination to allow for reactive adenopathy to resolve. This scheduling guidance should be incorporated based on the site’s available resources.